company background image
EDSA logo

Edesa Biotech NasdaqCM:EDSA Stock Report

Last Price

US$1.85

Market Cap

US$6.3m

7D

6.9%

1Y

-59.5%

Updated

27 Dec, 2024

Data

Company Financials +

Edesa Biotech, Inc.

NasdaqCM:EDSA Stock Report

Market Cap: US$6.3m

EDSA Stock Overview

A clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. More details

EDSA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 39.5% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($6M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Edesa Biotech, Inc. Competitors

Ainos

NasdaqCM:AIMD

US$6.6m

Galecto

NasdaqCM:GLTO

US$7.1m

Coeptis Therapeutics Holdings

NasdaqCM:COEP

US$8.7m

ABVC BioPharma

NasdaqCM:ABVC

US$6.8m

Price History & Performance

Summary of share price highs, lows and changes for Edesa Biotech
Historical stock prices
Current Share PriceUS$1.85
52 Week HighUS$5.99
52 Week LowUS$1.55
Beta0
1 Month Change-19.57%
3 Month Change-56.88%
1 Year Change-59.52%
3 Year Change-95.31%
5 Year Change-93.38%
Change since IPO-94.92%

Recent News & Updates

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Sep 23
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

Sep 07

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Aug 12

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

May 16
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Apr 18

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19
Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

Shareholder Returns

EDSAUS BiotechsUS Market
7D6.9%2.6%2.8%
1Y-59.5%-3.3%24.6%

Return vs Industry: EDSA underperformed the US Biotechs industry which returned -3.3% over the past year.

Return vs Market: EDSA underperformed the US Market which returned 24.6% over the past year.

Price Volatility

Is EDSA's price volatile compared to industry and market?
EDSA volatility
EDSA Average Weekly Movement11.4%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: EDSA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EDSA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201516Par Nijhawanwww.edesabiotech.com

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.

Edesa Biotech, Inc. Fundamentals Summary

How do Edesa Biotech's earnings and revenue compare to its market cap?
EDSA fundamental statistics
Market capUS$6.28m
Earnings (TTM)-US$6.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Is EDSA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EDSA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$6.17m
Earnings-US$6.17m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.78
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did EDSA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 23:01
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Edesa Biotech, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
David BautzZacks Small-Cap Research